Read More

Cidara Therapeutics Announces Divestiture Of Rezafungin To Mundipharma To Focus On Advancing The Clinical Development Of Cloudbreak DFC Pipeline; Transaction Provides Company With An Estimated ~$128M In Cost Savings

Transaction provides company with an estimated approximately $128 million in cost savings, including approximately $67 million in clinical development and CMC costs over the next three years and an additional

CDTX